Ongoing challenges for pharmacotherapy for dyslipidemia.

about

2016 Russell Ross Memorial Lecture in Vascular Biology: Molecular-Cellular Mechanisms in the Progression of Atherosclerosis.

P2860

Q48507796-6BC7F076-A6AC-4757-8032-7B205A0C6995

P2860

Ongoing challenges for pharmacotherapy for dyslipidemia.

Item

http://www.wikidata.org/entity/Q38283386

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Ongoing challenges for pharmacotherapy for dyslipidemia.

@en

type

Item

label

Ongoing challenges for pharmacotherapy for dyslipidemia.

@en

prefLabel

Ongoing challenges for pharmacotherapy for dyslipidemia.

@en

P1476

Ongoing challenges for pharmacotherapy for dyslipidemia.

@en

P2093

Anthony D Pisaniello

http://www.w3.org/2001/XMLSchema#string

Yu Kataoka

http://www.w3.org/2001/XMLSchema#string

P2860

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events

PCSK9: a key modulator of cardiovascular health

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association

Effect of torcetrapib on the progression of coronary atherosclerosis

Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

P304

347-356

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2014.986094

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stephen Nicholls

Daniel J Scherer

P577

2014-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25476544

http://www.w3.org/2001/XMLSchema#string

P921

dyslipidemias

pharmacotherapy

Ongoing challenges for pharmacotherapy for dyslipidemia.

about

P2860

P2860

Ongoing challenges for pharmacotherapy for dyslipidemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921